Targeting Melanin in Melanoma with Radionuclide Therapy
Nearly 100,000 individuals are expected to be diagnosed with melanoma in the United States in 2022. Treatment options for late-stage metastatic disease up until the 2010s were few and offered only slight improvement to the overall survival. The introduction of B-RAF inhibitors and anti-CTLA4 and ant...
Saved in:
| Published in | International journal of molecular sciences Vol. 23; no. 17; p. 9520 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
Basel
MDPI AG
01.09.2022
MDPI |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Nearly 100,000 individuals are expected to be diagnosed with melanoma in the United States in 2022. Treatment options for late-stage metastatic disease up until the 2010s were few and offered only slight improvement to the overall survival. The introduction of B-RAF inhibitors and anti-CTLA4 and anti-PD-1/PD-L1 immunotherapies into standard of care brought measurable increases in the overall survival across all stages of melanoma. Despite the improvement in the survival statistics, patients treated with targeted therapies and immunotherapies are subject to very serious side effects, the development of drug resistance, and the high costs of treatment. This leaves room for the development of novel approaches as well as for the exploration of novel combination therapies for the treatment of metastatic melanoma. One such approach is targeting melanin pigment with radionuclide therapy. Advances in melanin-targeting radionuclide therapy of melanoma can be viewed from two spheres: (1) radioimmunotherapy (RIT) and (2) radiolabeled small molecules. The investigation of mechanisms of the action and efficacy of targeting melanin in melanoma treatment by RIT points to the involvement of the immune system such as complement dependent cytotoxicity. The combination of RIT with immunotherapy presents synergistic killing in mouse melanoma models. The field of radiolabeled small molecules is focused on radioiodinated compounds that have the ability to cross the cellular membranes to access intracellular melanin and can be applied in both therapy and imaging as theranostics. Clinical applications of targeting melanin with radionuclide therapies have produced encouraging results and clinical work is on-going. Continued work on targeting melanin with radionuclide therapy as a monotherapy, or possibly in combination with standard of care agents, has the potential to strengthen the current treatment options for melanoma patients. |
|---|---|
| AbstractList | Nearly 100,000 individuals are expected to be diagnosed with melanoma in the United States in 2022. Treatment options for late-stage metastatic disease up until the 2010s were few and offered only slight improvement to the overall survival. The introduction of B-RAF inhibitors and anti-CTLA4 and anti-PD-1/PD-L1 immunotherapies into standard of care brought measurable increases in the overall survival across all stages of melanoma. Despite the improvement in the survival statistics, patients treated with targeted therapies and immunotherapies are subject to very serious side effects, the development of drug resistance, and the high costs of treatment. This leaves room for the development of novel approaches as well as for the exploration of novel combination therapies for the treatment of metastatic melanoma. One such approach is targeting melanin pigment with radionuclide therapy. Advances in melanin-targeting radionuclide therapy of melanoma can be viewed from two spheres: (1) radioimmunotherapy (RIT) and (2) radiolabeled small molecules. The investigation of mechanisms of the action and efficacy of targeting melanin in melanoma treatment by RIT points to the involvement of the immune system such as complement dependent cytotoxicity. The combination of RIT with immunotherapy presents synergistic killing in mouse melanoma models. The field of radiolabeled small molecules is focused on radioiodinated compounds that have the ability to cross the cellular membranes to access intracellular melanin and can be applied in both therapy and imaging as theranostics. Clinical applications of targeting melanin with radionuclide therapies have produced encouraging results and clinical work is on-going. Continued work on targeting melanin with radionuclide therapy as a monotherapy, or possibly in combination with standard of care agents, has the potential to strengthen the current treatment options for melanoma patients.Nearly 100,000 individuals are expected to be diagnosed with melanoma in the United States in 2022. Treatment options for late-stage metastatic disease up until the 2010s were few and offered only slight improvement to the overall survival. The introduction of B-RAF inhibitors and anti-CTLA4 and anti-PD-1/PD-L1 immunotherapies into standard of care brought measurable increases in the overall survival across all stages of melanoma. Despite the improvement in the survival statistics, patients treated with targeted therapies and immunotherapies are subject to very serious side effects, the development of drug resistance, and the high costs of treatment. This leaves room for the development of novel approaches as well as for the exploration of novel combination therapies for the treatment of metastatic melanoma. One such approach is targeting melanin pigment with radionuclide therapy. Advances in melanin-targeting radionuclide therapy of melanoma can be viewed from two spheres: (1) radioimmunotherapy (RIT) and (2) radiolabeled small molecules. The investigation of mechanisms of the action and efficacy of targeting melanin in melanoma treatment by RIT points to the involvement of the immune system such as complement dependent cytotoxicity. The combination of RIT with immunotherapy presents synergistic killing in mouse melanoma models. The field of radiolabeled small molecules is focused on radioiodinated compounds that have the ability to cross the cellular membranes to access intracellular melanin and can be applied in both therapy and imaging as theranostics. Clinical applications of targeting melanin with radionuclide therapies have produced encouraging results and clinical work is on-going. Continued work on targeting melanin with radionuclide therapy as a monotherapy, or possibly in combination with standard of care agents, has the potential to strengthen the current treatment options for melanoma patients. Nearly 100,000 individuals are expected to be diagnosed with melanoma in the United States in 2022. Treatment options for late-stage metastatic disease up until the 2010s were few and offered only slight improvement to the overall survival. The introduction of B-RAF inhibitors and anti-CTLA4 and anti-PD-1/PD-L1 immunotherapies into standard of care brought measurable increases in the overall survival across all stages of melanoma. Despite the improvement in the survival statistics, patients treated with targeted therapies and immunotherapies are subject to very serious side effects, the development of drug resistance, and the high costs of treatment. This leaves room for the development of novel approaches as well as for the exploration of novel combination therapies for the treatment of metastatic melanoma. One such approach is targeting melanin pigment with radionuclide therapy. Advances in melanin-targeting radionuclide therapy of melanoma can be viewed from two spheres: (1) radioimmunotherapy (RIT) and (2) radiolabeled small molecules. The investigation of mechanisms of the action and efficacy of targeting melanin in melanoma treatment by RIT points to the involvement of the immune system such as complement dependent cytotoxicity. The combination of RIT with immunotherapy presents synergistic killing in mouse melanoma models. The field of radiolabeled small molecules is focused on radioiodinated compounds that have the ability to cross the cellular membranes to access intracellular melanin and can be applied in both therapy and imaging as theranostics. Clinical applications of targeting melanin with radionuclide therapies have produced encouraging results and clinical work is on-going. Continued work on targeting melanin with radionuclide therapy as a monotherapy, or possibly in combination with standard of care agents, has the potential to strengthen the current treatment options for melanoma patients. |
| Author | Jiao, Rubin Malo, Mackenzie E. Allen, Kevin J. H. Dadachova, Ekaterina |
| AuthorAffiliation | College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada |
| AuthorAffiliation_xml | – name: College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada |
| Author_xml | – sequence: 1 givenname: Kevin J. H. surname: Allen fullname: Allen, Kevin J. H. – sequence: 2 givenname: Mackenzie E. orcidid: 0000-0002-9118-0806 surname: Malo fullname: Malo, Mackenzie E. – sequence: 3 givenname: Rubin surname: Jiao fullname: Jiao, Rubin – sequence: 4 givenname: Ekaterina surname: Dadachova fullname: Dadachova, Ekaterina |
| BookMark | eNptkU1LJDEQhsMysuPo3vwBDV48OGs-O8lFEHE_QBFkPId0unomQ3cyJt27zL_fuLrgilBQBfXUW7xVCzQLMQBCJwR_ZUzjC78dMmVEakHxJ3RIOKVLjGs5e1PP0SLnLcaUUaE_ozmrsaw15YdIrmxaw-jDurqD3gYfqhJ_yzjY6rcfN9WDbX0Mk-t9C9VqA8nu9sfooLN9hi-v-Qg9frtZXf9Y3t5__3l9dbt0TOlxyTkmYIWwurNWESlt01DGGSgteNtpcKSlHFxTd1Q4hQWwVikr27qRnCjKjtDli-5uagZoHYQx2d7skh9s2ptovfm_E_zGrOMvo7kQTMsicPYqkOLTBHk0g88O-mIQ4pQNlYQqUSvOCnr6Dt3GKYVi75kqxyRM6kLRF8qlmHOCzjg_2rFcqOz3vSHYPP_FvP1LGTp_N_TPwYf4Hw30j50 |
| CitedBy_id | crossref_primary_10_3390_pharmaceutics15061733 crossref_primary_10_3390_antiox11112166 crossref_primary_10_2174_0115680096283086240116093400 crossref_primary_10_1515_znc_2024_0043 crossref_primary_10_3390_ph16111622 crossref_primary_10_3390_cancers15153856 crossref_primary_10_3390_ijms24109081 |
| Cites_doi | 10.1056/NEJMoa1003466 10.1200/jco.2011.29.15_suppl.8509 10.1016/j.pharmthera.2021.107829 10.1038/s41598-018-23889-z 10.1200/JCO.2007.15.5465 10.1016/j.funbio.2017.08.010 10.1146/annurev.immunol.19.1.275 10.1038/s41577-020-0306-5 10.1016/j.funbio.2017.10.012 10.3389/fonc.2022.842496 10.1016/j.nucmedbio.2012.10.006 10.3390/cancers13061421 10.1093/intimm/dxu095 10.1186/s13046-018-0983-0 10.1111/j.1600-0749.1998.tb00736.x 10.1097/CMR.0b013e3282eeeae7 10.3390/pharmaceutics11070348 10.1088/1361-6498/ac3dcf 10.18632/oncotarget.7528 10.1016/j.ejmech.2015.01.034 10.1097/00008390-200204000-00003 10.1016/S0140-6736(89)90567-9 10.3390/ijms21186597 10.1111/j.1600-0749.1989.tb00196.x 10.1016/j.abb.2014.06.030 10.1001/jamadermatol.2014.1348 10.1128/IAI.68.5.2845-2853.2000 10.1158/0008-5472.CAN-09-4414 10.4161/cbt.7.7.6197 10.1016/S1470-2045(18)30497-2 10.1186/s12885-022-09495-3 10.3389/fimmu.2021.661737 10.1016/j.tranon.2019.07.015 10.1021/jm400877v 10.1016/0304-4165(86)90147-9 10.1016/S0738-081X(98)00023-6 10.18632/oncotarget.7340 10.3390/cells10112883 10.1016/j.jmir.2019.03.006 10.2967/jnumed.112.112789 10.3390/ijms21030773 10.1016/0891-5849(88)90049-4 10.1007/s00262-020-02606-8 10.1007/s10637-014-0086-5 10.1016/j.ijrobp.2010.02.020 10.1152/physrev.00044.2003 10.1016/j.humpath.2010.09.014 10.1684/ejd.2014.2481 10.3390/ijms21228721 10.1007/s00259-002-0971-6 10.1002/ijc.24005 10.1002/ijc.28103 10.3390/ijms23105731 10.1016/j.bmc.2015.02.017 10.1111/j.1468-3083.2008.03041.x 10.2217/imt.13.16 10.1002/mp.13165 10.1002/ijc.23664 10.3390/pharmaceutics10040262 10.3390/cells10112881 10.1073/pnas.0406180101 10.1080/0284186X.2020.1712473 |
| ContentType | Journal Article |
| Copyright | 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022 by the authors. 2022 |
| Copyright_xml | – notice: 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022 by the authors. 2022 |
| DBID | AAYXX CITATION 3V. 7X7 7XB 88E 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH K9. M0S M1P M2O MBDVC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM |
| DOI | 10.3390/ijms23179520 |
| DatabaseName | CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Research Library Research Library (Corporate) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef Publicly Available Content Database Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic CrossRef Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1422-0067 |
| ExternalDocumentID | PMC9455397 10_3390_ijms23179520 |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GroupedDBID | --- 29J 2WC 53G 5GY 5VS 7X7 88E 8FE 8FG 8FH 8FI 8FJ 8G5 A8Z AADQD AAFWJ AAHBH AAYXX ABDBF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV AEAQA AENEX AFKRA AFZYC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BCNDV BENPR BPHCQ BVXVI CCPQU CITATION CS3 D1I DIK DU5 DWQXO E3Z EBD EBS EJD ESX F5P FRP FYUFA GNUQQ GUQSH GX1 HH5 HMCUK HYE IAO IHR ITC KQ8 LK8 M1P M2O M48 MODMG O5R O5S OK1 OVT P2P PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RNS RPM TR2 TUS UKHRP ~8M 3V. 7XB 8FK K9. MBDVC PJZUB PKEHL PPXIY PQEST PQUKI PRINS Q9U 7X8 5PM |
| ID | FETCH-LOGICAL-c389t-4401ea55a9faa8177abb2343e8954df9ec1d24ecb6f25c805e3d88a7d6b741823 |
| IEDL.DBID | M48 |
| ISSN | 1422-0067 1661-6596 |
| IngestDate | Thu Aug 21 13:46:46 EDT 2025 Fri Jul 11 01:46:29 EDT 2025 Fri Jul 25 20:28:38 EDT 2025 Thu Apr 24 22:55:19 EDT 2025 Tue Jul 01 03:40:26 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 17 |
| Language | English |
| License | https://creativecommons.org/licenses/by/4.0 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c389t-4401ea55a9faa8177abb2343e8954df9ec1d24ecb6f25c805e3d88a7d6b741823 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 These authors contributed equally to this work. |
| ORCID | 0000-0002-9118-0806 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/ijms23179520 |
| PMID | 36076924 |
| PQID | 2711421379 |
| PQPubID | 2032341 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9455397 proquest_miscellaneous_2712856843 proquest_journals_2711421379 crossref_citationtrail_10_3390_ijms23179520 crossref_primary_10_3390_ijms23179520 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-09-01 |
| PublicationDateYYYYMMDD | 2022-09-01 |
| PublicationDate_xml | – month: 09 year: 2022 text: 2022-09-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Basel |
| PublicationPlace_xml | – name: Basel |
| PublicationTitle | International journal of molecular sciences |
| PublicationYear | 2022 |
| Publisher | MDPI AG MDPI |
| Publisher_xml | – name: MDPI AG – name: MDPI |
| References | Ribas (ref_9) 2011; 29 ref_50 Roszkowski (ref_23) 2016; 7 Pilas (ref_36) 1988; 4 Tsuboi (ref_14) 1998; 11 Schweitzer (ref_40) 2007; 17 Philips (ref_7) 2015; 27 Malo (ref_25) 2022; 42 Selbmann (ref_28) 2018; 122 Gardette (ref_59) 2014; 32 ref_51 Brandau (ref_54) 1996; 37 ref_18 ref_17 Slominski (ref_19) 2022; 12 Viallard (ref_63) 2015; 25 Klein (ref_42) 2013; 2013 Rosas (ref_38) 2000; 68 Billaud (ref_58) 2013; 56 Joyal (ref_57) 2010; 70 Ravetch (ref_44) 2001; 19 Desouky (ref_37) 2015; 8 Jozwicki (ref_24) 2011; 42 Billaud (ref_61) 2015; 92 Dadachova (ref_39) 2008; 7 ref_69 Jouberton (ref_64) 2018; 45 Labarre (ref_52) 2002; 12 Michelot (ref_53) 1993; 34 ref_65 Revskaya (ref_30) 2012; 27 Moser (ref_6) 2020; 59 Rouanet (ref_68) 2020; 69 Moins (ref_55) 2002; 29 Slominski (ref_22) 2004; 84 Dadachova (ref_33) 2004; 101 ref_72 Malo (ref_27) 2018; 122 VanMiddlesworth (ref_32) 2008; 123 Chang (ref_70) 2015; 23 Dummer (ref_11) 2018; 19 Zabierowski (ref_45) 2008; 26 Xu (ref_71) 2018; 37 Sarna (ref_34) 1986; 883 Mier (ref_56) 2014; 55 Degoul (ref_60) 2013; 133 Akil (ref_67) 2019; 12 Klein (ref_41) 2008; 49 Nosanchuk (ref_47) 2018; 8 Mishima (ref_15) 1989; 2 Slominski (ref_31) 1998; 16 Sarna (ref_35) 1999; 26 Jandl (ref_46) 2013; 40 Waldman (ref_4) 2020; 20 Lelliott (ref_8) 2021; 12 Gualandri (ref_12) 2009; 23 Rouanet (ref_62) 2021; 224 Thomas (ref_13) 2014; 150 Hodi (ref_5) 2010; 363 Slominski (ref_20) 2014; 563 Malo (ref_26) 2019; 50 Schweitzer (ref_29) 2010; 78 ref_1 Chapman (ref_10) 2011; 29 Slominski (ref_21) 2009; 124 ref_3 ref_2 Mishima (ref_16) 1989; 2 ref_49 Viallard (ref_66) 2016; 7 ref_48 Jandl (ref_43) 2013; 5 |
| References_xml | – volume: 363 start-page: 711 year: 2010 ident: ref_5 article-title: Improved survival with ipilimumab in patients with metastatic melanoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1003466 – volume: 29 start-page: 8509 year: 2011 ident: ref_9 article-title: BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma publication-title: J. Clin. Oncol. doi: 10.1200/jco.2011.29.15_suppl.8509 – volume: 224 start-page: 107829 year: 2021 ident: ref_62 article-title: Benzamide derivative radiotracers targeting melanin for melanoma imaging and therapy: Preclinical/clinical development and combination with other treatments publication-title: Pharmacol. Ther. doi: 10.1016/j.pharmthera.2021.107829 – volume: 8 start-page: 5466 year: 2018 ident: ref_47 article-title: Structure-function analysis and therapeutic efficacy of antibodies to fungal melanin for melanoma radioimmunotherapy publication-title: Sci. Rep. doi: 10.1038/s41598-018-23889-z – volume: 26 start-page: 2890 year: 2008 ident: ref_45 article-title: Melanoma stem cells: The dark seed of melanoma publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2007.15.5465 – volume: 122 start-page: 449 year: 2018 ident: ref_27 article-title: Morphological changes in melanized and non-melanized Cryptococcus neoformans cells post exposure to sparsely and densely ionizing radiation demonstrate protective effect of melanin publication-title: Fungal Biol. doi: 10.1016/j.funbio.2017.08.010 – volume: 19 start-page: 275 year: 2001 ident: ref_44 article-title: IgG Fc receptors publication-title: Annu. Rev. Immunol. doi: 10.1146/annurev.immunol.19.1.275 – volume: 20 start-page: 651 year: 2020 ident: ref_4 article-title: A guide to cancer immunotherapy: From T cell basic science to clinical practice publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-020-0306-5 – volume: 122 start-page: 546 year: 2018 ident: ref_28 article-title: Resistance of an Antarctic cryptoendolithic black fungus to radiation gives new insights of astrobiological relevance publication-title: Fungal Biol. doi: 10.1016/j.funbio.2017.10.012 – volume: 12 start-page: 842496 year: 2022 ident: ref_19 article-title: Melanoma, Melanin, and Melanogenesis: The Yin and Yang Relationship publication-title: Front. Oncol. doi: 10.3389/fonc.2022.842496 – volume: 40 start-page: 177 year: 2013 ident: ref_46 article-title: Melanoma stem cells in experimental melanoma are killed by radioimmunotherapy publication-title: Nucl. Med. Biol. doi: 10.1016/j.nucmedbio.2012.10.006 – ident: ref_69 doi: 10.3390/cancers13061421 – ident: ref_1 – volume: 27 start-page: 570 year: 2012 ident: ref_30 article-title: Compton Scattering by Internal Shields Based on Melanin-Containing Mushrooms Provides Protection of Gastrointestinal Tract from Ionizing Radiation publication-title: Cancer Biother. Radiopharm. – volume: 27 start-page: 39 year: 2015 ident: ref_7 article-title: Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies publication-title: Int. Immunol. doi: 10.1093/intimm/dxu095 – volume: 37 start-page: 306 year: 2018 ident: ref_71 article-title: Targeted radiotherapy of pigmented melanoma with (131)I-5-IPN publication-title: J. Exp. Clin. Cancer Res. doi: 10.1186/s13046-018-0983-0 – volume: 11 start-page: 275 year: 1998 ident: ref_14 article-title: Enhanced Melanogenesis Induced by Tyrosinase Gene-Transfer Increases Boron-Uptake and Killing Effect of Boron Neutron Capture Therapy for Amelanotic Melanoma publication-title: Pigment Cell Res. doi: 10.1111/j.1600-0749.1998.tb00736.x – volume: 17 start-page: 291 year: 2007 ident: ref_40 article-title: Computational model predicts effective delivery of 188-Re-labeled melanin-binding antibody to metastatic melanoma tumors with wide range of melanin concentrations publication-title: Melanoma Res. doi: 10.1097/CMR.0b013e3282eeeae7 – ident: ref_49 doi: 10.3390/pharmaceutics11070348 – volume: 42 start-page: 011508 year: 2022 ident: ref_25 article-title: Mitigating effects of sublethal and lethal whole-body gamma irradiation in a mouse model with soluble melanin publication-title: J. Radiol. Prot. doi: 10.1088/1361-6498/ac3dcf – volume: 7 start-page: 17844 year: 2016 ident: ref_23 article-title: Melanin content in melanoma metastases affects the outcome of radiotherapy publication-title: Oncotarget doi: 10.18632/oncotarget.7528 – volume: 92 start-page: 818 year: 2015 ident: ref_61 article-title: Synthesis, radiolabeling and preliminary in vivo evaluation of multimodal radiotracers for PET imaging and targeted radionuclide therapy of pigmented melanoma publication-title: Eur. J. Med. Chem. doi: 10.1016/j.ejmech.2015.01.034 – volume: 12 start-page: 15 year: 2002 ident: ref_52 article-title: Melanin affinity of N-(2-diethylaminoethyl)-4-iodobenzamide, an effective melanoma imaging agent publication-title: Melanoma Res. doi: 10.1097/00008390-200204000-00003 – volume: 2 start-page: 388 year: 1989 ident: ref_15 article-title: Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma-seeking 10B-compound publication-title: Lancet doi: 10.1016/S0140-6736(89)90567-9 – ident: ref_72 doi: 10.3390/ijms21186597 – volume: 2 start-page: 226 year: 1989 ident: ref_16 article-title: New thermal neutron capture therapy for malignant melanoma: Melanogenesis-seeking 10B molecule-melanoma cell interaction from in vitro to first clinical trial publication-title: Pigment Cell Res. doi: 10.1111/j.1600-0749.1989.tb00196.x – volume: 563 start-page: 79 year: 2014 ident: ref_20 article-title: The role of melanogenesis in regulation of melanoma behavior: Melanogenesis leads to stimulation of HIF-1α expression and HIF-dependent attendant pathways publication-title: Arch. Biochem. Biophys. doi: 10.1016/j.abb.2014.06.030 – volume: 8 start-page: 247 year: 2015 ident: ref_37 article-title: Targeted and non-targeted effects of ionizing radiation publication-title: J. Radiat. Res. Appl. Sci. – volume: 150 start-page: 1306 year: 2014 ident: ref_13 article-title: Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: A population-based study publication-title: JAMA Dermatol. doi: 10.1001/jamadermatol.2014.1348 – volume: 68 start-page: 2845 year: 2000 ident: ref_38 article-title: Synthesis of Polymerized Melanin by Cryptococcus neoformans in Infected Rodents publication-title: Infect. Immun. doi: 10.1128/IAI.68.5.2845-2853.2000 – volume: 26 start-page: 518 year: 1999 ident: ref_35 article-title: Free radical scavenging properties of melanin interaction of eu- and pheo-melanin models with reducing and oxidising radicals publication-title: Free Radic. Biol. Med. – volume: 70 start-page: 4045 year: 2010 ident: ref_57 article-title: Preclinical evaluation of an 131I-labeled benzamide for targeted radiotherapy of metastatic melanoma publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-09-4414 – volume: 7 start-page: 1116 year: 2008 ident: ref_39 article-title: Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with 188Re against experimental human metastatic melanoma in nude mice publication-title: Cancer Biol. Ther. doi: 10.4161/cbt.7.7.6197 – volume: 19 start-page: 1315 year: 2018 ident: ref_11 article-title: Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): A multicentre, open-label, Randomised Phase 3 Trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(18)30497-2 – ident: ref_65 doi: 10.1186/s12885-022-09495-3 – volume: 12 start-page: 661737 year: 2021 ident: ref_8 article-title: Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma publication-title: Front. Immunol. doi: 10.3389/fimmu.2021.661737 – volume: 12 start-page: 1442 year: 2019 ident: ref_67 article-title: Targeted Radionuclide Therapy Decreases Melanoma Lung Invasion by Modifying Epithelial-Mesenchymal Transition-Like Mechanisms publication-title: Transl. Oncol. doi: 10.1016/j.tranon.2019.07.015 – volume: 37 start-page: 1865 year: 1996 ident: ref_54 article-title: Structure distribution relationship of iodine-123-iodobenzamides as tracers for the detection of melanotic melanoma publication-title: J. Nucl. Med. – volume: 56 start-page: 8455 year: 2013 ident: ref_58 article-title: Synthesis, radiofluorination, and in vivo evaluation of novel fluorinated and iodinated radiotracers for PET imaging and targeted radionuclide therapy of melanoma publication-title: J. Med. Chem. doi: 10.1021/jm400877v – volume: 883 start-page: 162 year: 1986 ident: ref_34 article-title: Interaction of radicals from water radiolysis with melanin publication-title: Biochim. Biophys. Acta doi: 10.1016/0304-4165(86)90147-9 – volume: 16 start-page: 503 year: 1998 ident: ref_31 article-title: Animals under the sun: Effects of ultraviolet radiation on mammalian skin publication-title: Clin. Dermatol. doi: 10.1016/S0738-081X(98)00023-6 – volume: 7 start-page: 12927 year: 2016 ident: ref_66 article-title: Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy publication-title: Oncotarget doi: 10.18632/oncotarget.7340 – ident: ref_17 doi: 10.3390/cells10112883 – volume: 50 start-page: S2 year: 2019 ident: ref_26 article-title: Assessing Melanin Capabilities in Radiation Shielding and Radioadaptation publication-title: J. Med. Imaging Radiat. Sci. doi: 10.1016/j.jmir.2019.03.006 – volume: 55 start-page: 9 year: 2014 ident: ref_56 article-title: Radiopharmaceutical therapy of patients with metastasized melanoma with the melanin-binding benzamide 131I-BA52 publication-title: J. Nucl. Med. doi: 10.2967/jnumed.112.112789 – ident: ref_50 doi: 10.3390/ijms21030773 – volume: 4 start-page: 285 year: 1988 ident: ref_36 article-title: The effect of melanin on iron associated decomposition of hydrogen peroxide publication-title: Free Radic. Biol. Med. doi: 10.1016/0891-5849(88)90049-4 – volume: 69 start-page: 2075 year: 2020 ident: ref_68 article-title: Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy publication-title: Cancer Immunol. Immunother. doi: 10.1007/s00262-020-02606-8 – volume: 32 start-page: 587 year: 2014 ident: ref_59 article-title: Evaluation of two (125)I-radiolabeled acridine derivatives for Auger-electron radionuclide therapy of melanoma publication-title: Investig. New Drugs doi: 10.1007/s10637-014-0086-5 – volume: 78 start-page: 1494 year: 2010 ident: ref_29 article-title: Melanin-covered nanoparticles for protection of bone marrow during radiation therapy of cancer publication-title: Int. J. Radiat. Oncol. Biol. Phys. doi: 10.1016/j.ijrobp.2010.02.020 – volume: 84 start-page: 1155 year: 2004 ident: ref_22 article-title: Melanin Pigmentation in Mammalian Skin and Its Hormonal Regulation publication-title: Physiol. Rev. doi: 10.1152/physrev.00044.2003 – volume: 42 start-page: 618 year: 2011 ident: ref_24 article-title: Expression of vitamin D receptor decreases during progression of pigmented skin lesions publication-title: Hum. Pathol. doi: 10.1016/j.humpath.2010.09.014 – volume: 2013 start-page: 828329 year: 2013 ident: ref_42 article-title: Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma publication-title: J. Ski. Cancer – volume: 25 start-page: 29 year: 2015 ident: ref_63 article-title: [123I]ICF01012 melanoma imaging and [131I]ICF01012 dosimetry allow adapted internal targeted radiotherapy in preclinical melanoma models publication-title: Eur. J. Dermatol. doi: 10.1684/ejd.2014.2481 – ident: ref_51 doi: 10.3390/ijms21228721 – volume: 29 start-page: 1478 year: 2002 ident: ref_55 article-title: 123I-N-(2-diethylaminoethyl)-2-iodobenzamide: A potential imaging agent for cutaneous melanoma staging publication-title: Eur. J. Nucl. Med. Mol. Imaging doi: 10.1007/s00259-002-0971-6 – volume: 124 start-page: 1470 year: 2009 ident: ref_21 article-title: Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells publication-title: Int. J. Cancer doi: 10.1002/ijc.24005 – ident: ref_2 – volume: 133 start-page: 1042 year: 2013 ident: ref_60 article-title: In vivo efficacy of melanoma internal radionuclide therapy with a 131I-labelled melanin-targeting heteroarylcarboxamide molecule publication-title: Int. J. Cancer doi: 10.1002/ijc.28103 – volume: 29 start-page: LBA4 year: 2011 ident: ref_10 article-title: Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma publication-title: J. Clin. Oncol. – ident: ref_3 doi: 10.3390/ijms23105731 – volume: 23 start-page: 2261 year: 2015 ident: ref_70 article-title: Synthesis and evaluation of ¹²³/¹³¹I-Iochlonicotinamide as a novel SPECT probe for malignant melanoma publication-title: Bioorg. Med. Chem. doi: 10.1016/j.bmc.2015.02.017 – volume: 23 start-page: 283 year: 2009 ident: ref_12 article-title: Clinical features of 36 cases of amelanotic melanomas and considerations about the relationship between histologic subtypes and diagnostic delay publication-title: J. Eur. Acad. Dermatol. Venereol. doi: 10.1111/j.1468-3083.2008.03041.x – volume: 5 start-page: 357 year: 2013 ident: ref_43 article-title: Complement-dependent cytotoxicity of an antibody to melanin in radioimmunotherapy of metastatic melanoma publication-title: Immunotherapy doi: 10.2217/imt.13.16 – volume: 45 start-page: 5251 year: 2018 ident: ref_64 article-title: Radiation dosimetry of [(131) I]ICF01012 in rabbits: Application to targeted radionuclide therapy for human melanoma treatment publication-title: Med. Phys. doi: 10.1002/mp.13165 – volume: 49 start-page: 52P year: 2008 ident: ref_41 article-title: Imaging of metastatic melanoma (MM) with a 188Rhenium (188Re)-labeled melanin binding antibody publication-title: J. Nucl. Med. – volume: 123 start-page: 1448 year: 2008 ident: ref_32 article-title: Inhibition of melanogenesis as a radiation sensitizer for melanoma therapy publication-title: Int. J. Cancer doi: 10.1002/ijc.23664 – ident: ref_48 doi: 10.3390/pharmaceutics10040262 – ident: ref_18 doi: 10.3390/cells10112881 – volume: 101 start-page: 14865 year: 2004 ident: ref_33 article-title: Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.0406180101 – volume: 34 start-page: 1260 year: 1993 ident: ref_53 article-title: Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide) publication-title: J. Nucl. Med. – volume: 59 start-page: 434 year: 2020 ident: ref_6 article-title: Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma publication-title: Acta Oncol. doi: 10.1080/0284186X.2020.1712473 |
| SSID | ssj0023259 |
| Score | 2.4104507 |
| SecondaryResourceType | review_article |
| Snippet | Nearly 100,000 individuals are expected to be diagnosed with melanoma in the United States in 2022. Treatment options for late-stage metastatic disease up... |
| SourceID | pubmedcentral proquest crossref |
| SourceType | Open Access Repository Aggregation Database Enrichment Source Index Database |
| StartPage | 9520 |
| SubjectTerms | Antibodies Antigens Cancer therapies Clinical trials Cytotoxicity Dosimetry Free radicals Immunotherapy Ligands Medical prognosis Melanoma Metastasis Radiation Radiation therapy Review Scintigraphy Tumors |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LSwMxEA5aEbyIT6xWWUFPstjmnZOIWETQg1TobckmKVbabbXtwX_vTHb7OijsYSHDBmaymUcm30fIFQ2agtmx7hZ0yoURqe4JncJG6CSsmNxHENeXV_n0zp-7olsV3CZVW-V8T4wbtR85rJHfUoW3PltMmbvxV4qsUXi6WlFobJIthC7Dli7VXSZcjEaytBb4oFQKI8vGdwZp_m3_cziB0EYZgUzfqy5pGWeud0muuJ32Htmt4sXkvjTwPtkIxQHZLhkkfw6J6sRObvA_yUsY2KJfJPDE19HQJlhlTd6sB-XP3KDvQ9IpUQSOyHv7sfPwlFZcCKmDkGKacsiDghXCmp61uqWUzXPKOAvaCO57JriWpzy4XPaocLopAvNaW-Vljvg0lB2TWjEqwglJGCaFXpimzDXkO3gXVTr4fE6549qpOrmZqyNzFVA48lUMMkgYUHnZqvLq5HohPS4BMv6Qa8w1m1W_ySRbGrVOLhfDsMDx1MIWYTSLMlQLqTmrE7VmkcV8CJG9PlL0PyJUtuFCQMR1-v_kZ2SH4q2G2DrWILXp9yycQ6wxzS_igvoFDorSRA priority: 102 providerName: ProQuest |
| Title | Targeting Melanin in Melanoma with Radionuclide Therapy |
| URI | https://www.proquest.com/docview/2711421379 https://www.proquest.com/docview/2712856843 https://pubmed.ncbi.nlm.nih.gov/PMC9455397 |
| Volume | 23 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS8MwFD7MDWUv4hWnc1TQJ6m6NGmSBxGVzSFsyNhgbyVNM5xsne4C7t970m5zQ30RSikkaeGcpOf7knMBOCdGEFS73XczwqVMMld0mXDxR6h9nDFhlCRxrTf8Wps-d1gnA4tqo3MBjn-ldraeVHvUv_r8mN3hgr-1jBMp-3XvbTBGmMIlI0jec2iTuF2idbo8T0DYwGTq9v5jRB62PB_ZvCR03TZ9A851d8kV-1Pdge05cHTuU03vQsbEe7CZlpKc7QNvJS7daIicuumruBc7eCWPw4Fy7Har01QRamGq-73IOK00ncABtKuV1mPNnRdFcDVii4lLkRAZxZiSXaVEmXMVhsSjnhGS0agrjS5HhBod-l3CtLhhxouEUDzyQ5uohniHkI2HsTkCx7PsMGLyxg8FEh8blOprfH1IqKZC8wJcLsQR6HnGcFu4oh8gc7ByDFblWICLZe_3NFPGH_2KC8kGC3UHhNuY3rLHZQHOls040-3xhYrNcJr0IYL5gnoF4GsaWX7P5speb4l7r0nObEkZQ-h1_O-RJ5AnNvIhcS8rQnYymppTxCOTsAQbvMPxLqpPJcg9VBovzZK1EKyUTMIvuNbkwQ |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LaxsxEB5CQmkvJX1Rt2m6geZUlth661BCSRuch3MoDvi21UoydXHWaW1T8qf6GzOj9fpxaG-BPSxISDAzmoc08w3ABxYNQ7bTvVs0uZBW5mYoTY6K0CuUmDIkENfelepei_OBHGzB36YWhtIqG52YFHWYeLojP2Kaqj47XNvj2185dY2i19WmhUYtFhfx7g-GbNNPZ1-Qv4eMnX7tn3TzRVeB3KNxnuUCI4ropHR26JzpaO3KknHBo7FShKGNvhOYiL5UQya9acvIgzFOB1US0gsBHaDK30HD26YTpQerAI-z1JytgzYvV9KqOtGec9s-Gv28maIrpa2kzuLrJnDl125mZa6ZudNdeLrwT7PPtUA9g61YPYdHdcfKuxeg-ylzHO1d1otjV42qDL_0O7lxGd3qZt9cQGbP_XgUYtavUQtewvWDUOkVbFeTKr6GjFMQGqRtq9JgfEW1r8rj8iUTXhivW_CxIUfhF8Dk1B9jXGCAQsQr1onXgsPl7NsakOMf8_YayhaLYzktVkLUgoPlMB4oeiVxVZzM0xxmpDKCt0BvcGS5H0Fyb45Uox8JmtsKKdHDe_P_zd_D426_d1lcnl1dvIUnjCoqUtraHmzPfs_jO_RzZuV-Eq4Mvj-0NN8DKrQPbg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LaxRBEC5CRPEiPnE16gjmJMPu9LsPIiFxSYwJIhvY29jT3UNWNrPR3UXy1_x1Vs1jHwe9BeYw0E03VFXXo7vqK4B3LBqGbKd7t2hSIa1MTSlNiorQK5SYItQgrmfn6vhCfB7L8Q786WphKK2y04m1og4zT3fkfaap6jPj2vbLNi3i69Hw4_XPlDpI0Utr106jEZHTePMbw7f5h5Mj5PU-Y8NPo8PjtO0wkHo01ItUYHQRnZTOls6ZTGtXFIwLHo2VIpQ2-iwwEX2hSia9GcjIgzFOB1UQ6guBHqD6v6O5zOiM6fE62OOsbtSWof1LlbSqSbrn3A76kx9Xc3SrtJXUZXzTHK593O0MzQ2TN3wID1pfNTlohOsR7MTqMdxtulfePAE9qrPI0fYlZ3HqqkmV4Ff_zq5cQje8yTcXkPFLP52EmIwaBIOncHErVHoGu9Wsis8h4RSQBmkHqjAYa1EdrPK4fMGEF8brHrzvyJH7FqScemVMcwxWiHj5JvF6sL-afd2Ac_xj3l5H2bw9ovN8LVA9eLsaxsNFLyauirNlPYcZqYzgPdBbHFntR_Dc2yPV5LKG6bZCSvT2Xvx_8zdwD-U4_3JyfvoS7jMqrqgz2PZgd_FrGV-hy7MoXteylcD32xbmv5AVE6Q |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeting+Melanin+in+Melanoma+with+Radionuclide+Therapy&rft.jtitle=International+journal+of+molecular+sciences&rft.au=Allen%2C+Kevin+J.+H.&rft.au=Malo%2C+Mackenzie+E.&rft.au=Jiao%2C+Rubin&rft.au=Dadachova%2C+Ekaterina&rft.date=2022-09-01&rft.pub=MDPI&rft.eissn=1422-0067&rft.volume=23&rft.issue=17&rft_id=info:doi/10.3390%2Fijms23179520&rft_id=info%3Apmid%2F36076924&rft.externalDocID=PMC9455397 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1422-0067&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1422-0067&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1422-0067&client=summon |